VVOS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -7.97%, SMA50 -21.71%, SMA200 -51.89%). The stock’s 14-day RSI is 34.7 (weak momentum), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.76% below its high and over 1.86% above its low. Average 10-day trading volume of 92.21 million shares is significantly above the 3-month average of 11.17 million, indicating heightened recent market interest.

Vivos Therapeutics, Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 32.77%. The latest quarter delivered EPS of -$0.31. The next quarter is forecast at -$0.48. Next year's EPS is expected at $59.76. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.50. The high target offers 3400.0% upside. The low target suggests 1150.0% downside. The mean target is $4.77. This offers 2285.0% upside. Vivos Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 14, 2026, missed forecasts by -24.39%. The prior quarter beat by 44.44%. Over the last six quarters, Apple has recorded several small beats. These include 2.27% in May 15, 2025.

Vivos Therapeutics, Inc. has 20.12 million shares outstanding. The public float is 16.55 million shares, elevated short interest at 10.81% of float. This equals 1.20 million shares. The short ratio is 1.61 days. Institutional investors hold 7.96% of the float. Insiders own 18.2%. Skaff Michael C holds 859.17 thousand shares, Huntsman Ronald Kirk has 86.52 thousand shares and Amman Bradford K. has 2.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) closed at $0.20 USD, losing -$0.03 (-12.85%) from the previous close of $0.22. The stock is currently mid-range between its 52-week high and low $0.17 and $4.62. With a market capitalization of about $2.72 million, Vivos Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~6.09). Key stats such as the average daily volume over the past year has been around 11.29 million shares, trading with heavier-than-usual volume. Headquartered in Littleton, CO, Vivos Therapeutics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO R. Kirk Huntsman, the company employs approximately 268 people and listed since December 11, 2020. Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

Vivos Therapeutics, Inc. trades at a P/E ratio of -0.1, slightly below the S&P 500 average, with a price-to-sales ratio of 0.14 and a price-to-book ratio of -0.94 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.16, also above market averages.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares are flat -2.96% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vivos Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.03, suggesting 2466.33% upside. Our AI forecast model points to short-term weakness (-28.57% over two weeks), a medium-term fall (-89.8% over three months), and a longer-term loss (-89.8% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Vivos Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -28.57%, with price expected at $0.14 by September 14, 2026, within a range of $0.11 to $0.18 3-Month Outlook: Projected fall of -89.8%, reaching $0.02 by November 26, 2026, with a range of $0.00 to $0.10. 1-Year Outlook: Projected loss of -89.8%, with price at $0.02 by August 31, 2027, within a range of $0.00 to $0.59.